BRISTOL-MYERS SQUIBB COMPANY Gain (Loss) on Investments
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Gain (Loss) on Investments of $114.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for the quarter ending 2026-06-30 was $114.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for the quarter ending 2026-03-31 was $134.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for the quarter ending 2025-12-31 was $190.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for the quarter ending 2025-09-30 was $190.00M, a 1483.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for fiscal 2025 was $280.00M, a 1650.00% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for fiscal 2024 was $16.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for fiscal 2023 was -$160.00M.
- BRISTOL-MYERS SQUIBB COMPANY gain (loss) on investments for fiscal 2022 was -$801.00M, a 207.52% decline from fiscal 2021.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $114.00M 10-Q · filed 2026-07-30 | $248.00M 10-Q · filed 2026-07-30 | $438.00M derived: sum of 3 quarters · filed 2026-07-30 | $628.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $134.00M 10-Q · filed 2026-04-30 | $324.00M derived: sum of 2 quarters · filed 2026-04-30 | $514.00M derived: sum of 3 quarters · filed 2026-04-30 | $492.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $380.00M derived: sum of 2 quarters · filed 2026-02-11 | $358.00M derived: sum of 3 quarters · filed 2026-07-30 | $280.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $190.00M 10-Q · filed 2025-10-30 | $168.00M derived: sum of 2 quarters · filed 2026-07-30 | $90.00M 10-Q · filed 2025-10-30 | -$115.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$22.00M 10-Q · filed 2026-07-30 | -$100.00M 10-Q · filed 2026-07-30 | -$305.00M derived: sum of 3 quarters · filed 2026-07-30 | -$293.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$78.00M 10-Q · filed 2026-04-30 | -$283.00M derived: sum of 2 quarters · filed 2026-04-30 | -$271.00M derived: sum of 3 quarters · filed 2026-04-30 | -$164.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$205.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$193.00M derived: sum of 2 quarters · filed 2026-02-11 | -$86.00M derived: sum of 3 quarters · filed 2026-02-11 | $16.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $12.00M 10-Q · filed 2025-10-30 | $119.00M derived: sum of 2 quarters · filed 2025-10-30 | $221.00M 10-Q · filed 2025-10-30 | $274.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $107.00M 10-Q · filed 2025-07-31 | $209.00M 10-Q · filed 2025-07-31 | $262.00M derived: sum of 3 quarters · filed 2026-02-11 | $262.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $102.00M 10-Q · filed 2025-04-24 | $155.00M derived: sum of 2 quarters · filed 2026-02-11 | $155.00M derived: sum of 3 quarters · filed 2026-02-11 | $97.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $53.00M derived: sum of 2 quarters · filed 2026-02-11 | -$5.00M derived: sum of 3 quarters · filed 2026-02-11 | -$160.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-31 | -$58.00M derived: sum of 2 quarters · filed 2024-10-31 | -$213.00M 10-Q · filed 2024-10-31 | -$48.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -$58.00M 10-Q · filed 2024-07-26 | -$213.00M 10-Q · filed 2024-07-26 | -$48.00M derived: sum of 3 quarters · filed 2025-02-12 | -$62.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$155.00M 10-Q · filed 2024-04-25 | $10.00M derived: sum of 2 quarters · filed 2025-02-12 | -$4.00M derived: sum of 3 quarters · filed 2025-02-12 | -$312.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $151.00M derived: sum of 2 quarters · filed 2025-02-12 | -$157.00M derived: sum of 3 quarters · filed 2025-02-12 | -$801.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$14.00M 10-Q · filed 2023-10-26 | -$322.00M derived: sum of 2 quarters · filed 2023-10-26 | -$966.00M 10-Q · filed 2023-10-26 | -$1.44B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | -$308.00M 10-Q · filed 2023-07-27 | -$952.00M 10-Q · filed 2023-07-27 | -$1.42B derived: sum of 3 quarters · filed 2024-02-13 | -$956.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | -$644.00M 10-Q · filed 2023-04-27 | -$1.11B derived: sum of 2 quarters · filed 2024-02-13 | -$648.00M derived: sum of 3 quarters · filed 2024-02-13 | -$500.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | -$469.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$4.00M derived: sum of 2 quarters · filed 2024-02-13 | $144.00M derived: sum of 3 quarters · filed 2024-02-13 | $745.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $465.00M 10-Q · filed 2022-10-26 | $613.00M derived: sum of 2 quarters · filed 2022-10-26 | $1.21B 10-Q · filed 2022-10-26 | $1.72B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $148.00M 10-Q · filed 2022-07-27 | $749.00M 10-Q · filed 2022-07-27 | $1.25B derived: sum of 3 quarters · filed 2023-02-14 | $1.50B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $601.00M 10-Q · filed 2022-04-29 | $1.10B derived: sum of 2 quarters · filed 2023-02-14 | $1.35B derived: sum of 3 quarters · filed 2023-02-14 | |
| 2020-12-31 | $504.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $748.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.23B 10-K · filed 2023-02-14 | |
| 2020-09-30 | $244.00M 10-Q · filed 2021-10-27 | $724.00M 10-Q · filed 2021-10-27 | ||
| 2018-09-30 | $97.00M 10-Q · filed 2018-10-25 | -$259.00M derived: sum of 2 quarters · filed 2018-10-25 | -$244.00M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | -$356.00M 10-Q · filed 2018-07-26 | -$341.00M 10-Q · filed 2018-07-26 | ||
| 2018-03-31 | $15.00M 10-Q · filed 2018-04-26 | |||
| 2017-09-30 | $5.00M 10-Q · filed 2018-10-25 | $10.00M derived: sum of 2 quarters · filed 2018-10-25 | $17.00M 10-Q · filed 2018-10-25 | |
| 2017-06-30 | $5.00M 10-Q · filed 2018-07-26 | $12.00M 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $7.00M 10-Q · filed 2018-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |